Suppr超能文献

罗哌卡因注射用乳剂与地塞米松磷酸钠混合后的相容性和稳定性

Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate.

作者信息

Wu George, Yeung Stanley, Chen Frank

机构信息

TESARO Inc., Waltham, Massachusetts.

出版信息

Int J Pharm Compd. 2017 Jan-Feb;21(1):66-75.

Abstract

Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone combination therapy is the standard of care for the prevention of chemotherapy-induced nausea and vomiting. Herein, we describe the physical and chemical stability of an injectable emulsion of the Neurokinin-1 receptor antagonist rolapitant 185 mg in 92.5 mL (free base, 166.5 mg in 92.5 mL) admixed with either 2.5 mL of dexamethasone sodium phosphate (10 mg) or 5 mL of dexamethasone sodium phosphate (20 mg). Admixtures were prepared and stored in two types of container closures (glass and Crystal Zenith plastic bottles) and four types of intravenous administration tubing sets (or intravenous tubing sets). The assessment of the physical and chemical stability was conducted on admixtures packaged in bottled samples stored at room temperature (20°C to 25°C under fluorescent light) and evaluated at 0, 1, and 6 hours. For admixtures in intravenous tubing sets, the assessment of physicochemical stability was performed after 0 and 7 hours of storage at 20°C to 25°C, and then after 20 hours (total 27 hours) under refrigeration (2°C to 8°C) and protected from light. Physical stability was assessed by visually examining the bottle contents under normal room light and measuring turbidity and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations through high-performance liquid chromatographic analysis. Results showed that all samples were physically compatible throughout the duration of the study. The admixtures stayed within narrow and acceptable ranges in pH, turbidity, and particulate matter. Admixtures of rolapitant and dexamethasone were chemically stable when stored in glass and Crystal Zenith bottles for at least 6 hours at room temperature, as well as in the four selected intravenous tubing sets for 7 hours at 20°C to 25°C and then for 20 (total 27 hours) hours at 2°C to 8°C. No loss of potency of any admixed component occurred in the samples stored at the temperature ranges studied.

摘要

神经激肽-1受体拮抗剂、5-羟色胺-3受体拮抗剂和地塞米松联合疗法是预防化疗引起的恶心和呕吐的标准治疗方法。在此,我们描述了神经激肽-1受体拮抗剂罗拉匹坦185毫克(游离碱,92.5毫升中含166.5毫克)与2.5毫升地塞米松磷酸钠(10毫克)或5毫升地塞米松磷酸钠(20毫克)混合而成的注射用乳剂的物理和化学稳定性。混合制剂采用两种类型的容器密封(玻璃瓶和晶顶塑料瓶)和四种类型的静脉输液管(或静脉输液器)进行制备和储存。对包装在瓶装样品中的混合制剂在室温(荧光灯下20°C至25°C)下储存,并在0、1和6小时进行评估,以测定其物理和化学稳定性。对于静脉输液管中的混合制剂,在20°C至25°C下储存0和7小时后,然后在冷藏(2°C至8°C)且避光条件下储存20小时(共27小时)后,进行物理化学稳定性评估。通过在正常室内光线下目视检查瓶内内容物并测量浊度和颗粒物来评估物理稳定性。通过测量混合制剂的pH值并通过高效液相色谱分析确定药物浓度来评估化学稳定性。结果表明,在整个研究期间所有样品在物理上都是相容的。混合制剂的pH值、浊度和颗粒物均保持在狭窄且可接受的范围内。罗拉匹坦和地塞米松的混合制剂在玻璃瓶和晶顶塑料瓶中于室温下储存至少6小时,以及在四种选定的静脉输液管中于20°C至25°C下储存7小时,然后在2°C至8°C下储存20小时(共27小时)时,化学性质稳定。在所研究的温度范围内储存的样品中,任何混合成分均未出现效力损失。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验